Brian Gremillion, MD
Internal Medicine · Baton Rouge, LANPI 1326049545
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 1,629 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,629 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AbbVie$2K
- AstraZeneca$2K
- Lilly USA, LLC$2K
- Boehringer Ingelheim$2K
- Amgen$1K
- plus $15K from 54 others
What the payments were for
- Food & beverage$27,174100%
- Education$1000%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,274 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 114 | $446,313 |
| JardianceEmpagliflozin | 354 | $328,744 |
| MounjaroTirzepatide | 245 | $310,357 |
| OzempicSemaglutide | 206 | $210,560 |
| EliquisApixaban | 495 | $195,376 |
| TrulicityDulaglutide | 132 | $152,890 |
| FarxigaDapagliflozin Propanediol | 160 | $141,519 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 160 | $136,526 |
| Bexarotene | 11 | $126,435 |
| TradjentaLinagliptin | 147 | $123,474 |
| JanuviaSitagliptin Phosphate | 269 | $122,285 |
| EnbrelEtanercept | 12 | $95,852 |
| XifaxanRifaximin | 55 | $91,401 |
| XareltoRivaroxaban | 178 | $81,227 |
| RexultiBrexpiprazole | 87 | $78,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $2,026 | $463,247377 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,570 | $452,217501 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $49 | $446,313114 claims |
| Novo NordiskOzempic | $2,882 | $210,560206 claims |
| PfizerEliquis | $1,048 | $195,376495 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,148 | $161,155218 claims |
| MerckJanuvia, Janumet | $449 | $145,675298 claims |
| Johnson & JohnsonXarelto, Invega Sustenna, Risperdal Consta | $1,025 | $143,988209 claims |
| AstraZenecaFarxiga | $2,333 | $141,519160 claims |
| AmgenEnbrel | $1,210 | $95,85212 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $173 | $91,40155 claims |
| AbbVieLinzess, Vraylar | $2,419 | $87,477128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Baton Rouge
- Donna RyanBaton Rouge$991K
- John SchwabBaton Rouge$122K
- Barret MurphyBaton Rouge$43K
- Bradley MeekBaton Rouge$20K
- Leo BlaizeBaton Rouge$17K
- Michael HymbaughBaton Rouge$16K
- Kyle ChampagneBaton Rouge$16K
- Charles HalliburtonBaton Rouge$16K
- Hartman BruntBaton Rouge$15K
- Lauren BarfieldBaton Rouge$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.